Earlier Detection.
Better Health.
Our Vision
A world where cancer is overcome by early detection and informed treatment.
Our Mission
Accelerating the world towards people living longer and healthier lives,
enabled by earlier and non-invasive detection of cancer and other aging diseases.
About Us
Earlier Detection.
Better Health.
What if health conditions could be detected earlier before symptoms show up, when prevention is possible?
At Lucence, we believe that earlier detection is the key to longevity by advancing detection before symptoms even appear. Our ultrasensitive tests deliver insights to guide doctors in providing you with a personalized health action plan.
Everyone’s story is unique. Our wide range of tests aim ensure that there’s a test that fits into everyone’s story. We are here with you at every step of your health journey.
Milestones
2016
Company founded as a spin-off from the Agency for Science, Technology and Research (A* STAR) in Singapore
2017
-
Raised $9.2M in seed funding
-
Received Clinical Laboratory License in Singapore
2018
-
Launched flagship test, LiquidHALLMARK for therapy selection
-
Expanded operations to Hong Kong
2019
-
Raised $20M Series A Led by IHH healthcare
-
Singapore Laboratory received federal CLIA license, California out-of-state license and CAP accreditation
2020
-
Developed AmpliMARK as our core liquid biopsy technology platform
-
Expanded operations to the United States
-
Palo Alto Lab received California state license and federal CLIA license
2021
-
Palo Alto Lab received CAP accreditation
-
Launched LIQUIK, a multicenter prospective head-to-head study in US and Singapore
2022
Expanded US LiquidHALLMARK profiling to include both ctDNA and ctRNA for greater accuracy in therapy selection
2023
-
Achieved US Medicare coverage for LiquidHALLMARK
-
Launched LucenceINSIGHT, establishing the world's first multi-cancer early detection (MCED) test spanning cancer mutations and cancer-causing viruses
2025
-
Formed strategic collaboration with Mayo Clinic Laboratories to increase LiquidHALLMARK access in US
-
Published LIQUIK, a multicenter prospective head-to-head study that demonstrated superiority of LiquidHALLMARK against an FDA-approved test
-
Expanded service range beyond multi-cancer screening to multi-disease screening with the launch of LucenceLONGEVITY™
-
Expanded commercial operations to markets of India and ASEAN
Our Laboratories
SINGAPORE
211 Henderson Road, #04-01/02,
Henderson Industrial Park, S159552
Tel: (65) 6909 0390 | Fax: (65) 6725 0590
PALO ALTO
3520 W Bayshore Road, Palo Alto,
CA 94303
Tel: (888) 582 3623
HONG KONG
Suite 1018, Unit 1001, 10/F, Mira Place Tower A, 132 Nathan Road, Tsim Sha Tsui, Kowloon, Hong Kong
Tel: (852) 5182 7199 | Fax: (852) 3012 9866
Our strategic collaborator
Our research collaborators
MD Anderson Cancer Center
